

No: 07./TKKT

Ho Chi Minh City, January 20, 2025

To: - State Securities Commission of Vietnam
- Hanoi Stock Exchange

Subject: Explanation of the consolidated business performance results for Quarter and the full year 2024 with a discrepancy of more than 10% compared to the same period in 2023

Pursuant to the regulations under Circular 96/2020/TT-BTC on public disclosure in the securities market, Mekophar Chemical and Pharmaceutical Joint Stock Company (Stock code: MKP) provides an explanation of the consolidated business performance results for Quarter and the full year 2024 with a difference of more than 10% compared to the same period in 2023 as follows::

1. Results for Quarter 2024 compared to Quarter 2023 (the consolidated Report):

| Indicator | Quarter 2024 | Quarter 2023 | Difference | (%) |
|-------------------------|-----------------|-----------------|------------------|--------|
| Revenue | 244.810.872.705 | 253.207.284.671 | - 8.396.411.966 | -3,3% |
| Cost of Goods Sold | 179.109.879.226 | 174.834.983.734 | 4.274.895.492 | 2,4% |
| Selling Expenses | 26.250.533.363 | 28.023.835.275 | - 1.773.301.912 | -6,3% |
| Administrative Expenses | 40.414.076.224 | 51.604.134.718 | - 11.190.058.494 | -21,7% |
| Financial Revenue | 38.149.948.399 | 14.264.956.967 | 23.884.991.432 | 167,4% |
| Net Profit After Tax | 28.885.148.995 | 17.654.619.937 | 11.230.529.058 | 63,6% |

Reason: The net profit after tax for Quarter 2024 increased by 63.6% mainly due to income from financial investments.

2. Results for 2024 compared to 2023 (the consolidated Report):

| Indicator | Quarter 2024 | Quarter 2023 | Difference | (%) |
|-------------------------|-----------------|-----------------|-----------------|--------|
| Revenue | 919.583.349.082 | 904.838.743.436 | 14.744.605.646 | 1,6% |
| Cost of Goods Sold | 671.520.897.763 | 637.368.901.371 | 34.151.996.392 | 5,4% |
| Selling Expenses | 110.356.307.641 | 108.591.717.591 | 1.764.590.050 | 1,6% |
| Administrative Expenses | 144.878.523.920 | 151.740.435.938 | - 6.861.912.018 | -4,5% |
| Financial Revenue | 66.436.618.579 | 24.884.010.729 | 41.552.607.850 | 167,0% |
| Net Profit After Tax | 42.263.025.646 | 25.114.127.514 | 17.148.898.132 | 68,3% |

Reason: The net profit after tax for 2024 increased by 68.3% mainly due to income from financial investments.

This information has been published on the Company's website at: <https://mekophar.com/> in the "Investor Relations" section.

The Company affirms that the information provided is accurate and takes full responsibility for the disclosed content.

Recipient:

- As above
- Archive



GENERAL DIRECTOR *[Signature]*

Pharm. Huỳnh Chi Lan